Paroxysmal Nocturnal Hemoglobinuria clinical trials at UCLA
1 research study open to eligible people
Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
open to all eligible people
A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.
Los Angeles, California and other locations
Our lead scientists for Paroxysmal Nocturnal Hemoglobinuria research studies include Caspian Oliai.